🔗 Share this article

Given that the US continues making unprecedented changes to its vaccine guidelines, a particular individual appears unexpectedly: Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by expressing skepticism about Covid shots throughout the pandemic and has zeroed in on alleged deaths following Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Immunization Schedule

Public health authorities were set to unveil sweeping changes to the pediatric vaccination calendar in December, aligning the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US out of step with many the global community with little proof for public health gain. The planned update has been pushed back until the next year.

Rather than the top vaccines chief, Høeg is scheduled to present at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the center this year.

Consolidating Power at the Agency

Høeg's temporary position could signify a closer partnership between the drug and vaccine centers as Høeg and Dr. Prasad consolidate power at the agency – and it signals a greater focus upon reevaluating already-approved immunizations at the FDA.

Høeg has frequently advocated for halting some childhood immunization guidelines in the US so as to align more in line with Denmark's approach, a country with comprehensive healthcare and a number of inhabitants roughly the population of Wisconsin’s.

So far statements, she has continued to focus on vaccines – typically the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Expertise

The appointee has little discernible background in medication creation, oversight or administrative roles, which has been typical for former leaders of the biologics center. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in managing a sizeable institution. She lacks background in pharmaceutical oversight.”

Former directors of the center would “understand laws and regulations and the research of drug development”, said Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that prior appointees who ran CBER have had.”

This division has an vast range of responsibilities at the agency, the former commissioner pointed out.

“Many people just focuses on the new drug program, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and more, and each of these must be looked after,” Dr. Woodcock said. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a substantial management aspect to the position, which supervises over 5,000 employees. “It is a enormous administrative position, if you perform it correctly,” Woodcock added.

Official Statement and Contentious Policies

When asked about concerns about Dr. Høeg's qualifications and whether this appointment indicates greater collaboration among regulatory chiefs on vaccines, a spokesperson said that the “concerns are based on incorrect presumptions”.

“Her experience is consistent with the responsibilities of her job,” the official said, citing the period Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's controversial priority voucher program, a contentious rapid drug-approval program that apparently troubled her preceding directors. “By what process are these drugs being chosen for this voucher program? Who takes the choices?” Howard said. “There’s a lot of lack of transparency occurring at the agency right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards laxer oversight of pharmaceuticals, with the exception of immunizations.”

Public History on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if concerning, track record, some experts said. She authored a study using non-validated public submissions to estimate the rate of myocarditis after COVID-19 vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to imply Covid vaccinations are riskier than they are.

Part of her “wish list” for the incoming administration included revising guidelines for recently developed shots and discontinuing “non-essential” immunizations, she said after the election on a podcast. At the agency, Høeg has according to sources floated the idea of barring adolescent males from obtaining COVID-19 vaccinations.

“She is an thorough dogmatist who starts off with her preconceived notions and tailors the evidence to fit the evidence in a very deceptive, untruthful manner,” Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg aligned with fellow contrarians, {like|